Insignificant disease among men with intermediate-risk prostate cancer

被引：0
|
作者：
Sung Kyu Hong
Emily Vertosick
Daniel D. Sjoberg
Peter T. Scardino
James A. Eastham
机构：
[1] Memorial Sloan-Kettering Cancer Center,Urology Service, Department of Surgery
[2] Seoul National University Bundang Hospital,Department of Urology
[3] Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics
[4] Cornell University,Department of Urology, Weill Cornell Medical College
来源：
World Journal of Urology | 2014年 / 32卷
关键词：
Prostate; Prostatic neoplasms; Insignificant; Intermediate risk; Prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1417 / 1421
页数：4
相关论文
共 50 条
  • [21] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
    Ju, Andrew W.
    Wang, Hongkun
    Oermann, Eric K.
    Sherer, Benjamin A.
    Uhm, Sunghae
    Chen, Viola J.
    Pendharkar, Arjun V.
    Hanscom, Heather N.
    Kim, Joy S.
    Lei, Siyuan
    Suy, Simeng
    Lynch, John H.
    Dritschilo, Anatoly
    Collins, Sean P.
    RADIATION ONCOLOGY, 2013, 8
  • [22] Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone
    Faria, Sergio
    Dal Pra, Alan
    Cury, Fabio
    David, Marc
    Duclos, Marie
    Freeman, Carolyn R.
    Souhami, Luis
    RADIOTHERAPY AND ONCOLOGY, 2011, 101 (03) : 486 - 489
  • [23] Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
    Andrew W Ju
    Hongkun Wang
    Eric K Oermann
    Benjamin A Sherer
    Sunghae Uhm
    Viola J Chen
    Arjun V Pendharkar
    Heather N Hanscom
    Joy S Kim
    Siyuan Lei
    Simeng Suy
    John H Lynch
    Anatoly Dritschilo
    Sean P Collins
    Radiation Oncology, 8
  • [24] A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates
    Hahn, Andrew W.
    Manyam, Ganiraju C.
    Chapin, Brian F.
    Zhang, Miao
    Yu, Yao
    Pettaway, Curtis A.
    Chery, Lisly
    Pisters, Louis L.
    Ward, John F.
    Gregg, Justin R.
    Papadopoulos, John
    Kamat, Ashish M.
    Lozano, Marisa
    Hoang, Anh
    Broom, Bradley
    Wang, Xuemei
    Huff, Chad D.
    Logothetis, Christopher J.
    Troncoso, Patricia
    Pilie, Patrick G.
    Davis, John W.
    BJU INTERNATIONAL, 2024, 134 (03) : 449 - 458
  • [25] Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer
    Yassa, Michael
    Fortin, Bernard
    Fortin, Marie-Andree
    Lambert, Carole
    Nguyen, Thu Van
    Bahary, Jean-Paul
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (01): : 58 - 63
  • [26] The significance of surgical staging in intermediate-risk endometrial cancer
    Kwon, Janice S.
    Mazgani, Mona
    Miller, Dianne M.
    Ehlen, Tom
    Heywood, Mark
    McAlpine, Jessica N.
    Finlayson, Sarah J.
    Plante, Marie
    Stuart, Gavin C. E.
    Carey, Mark S.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 50 - 54
  • [27] Sociodemographic Predictors of Prostate Cancer Risk Category at Diagnosis: Unique Patterns of Significant and Insignificant Disease
    Dall'Era, Marc A.
    Hosang, Nap
    Konety, Badrinath
    Janet, E. Cowan
    Carroll, Peter R.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 1622 - 1627
  • [28] Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy
    Andruska, Neal
    Fischer-Valuck, Benjamin W.
    Waters, Michael
    Diaz, Elizabeth Juarez
    Agabalogun, Temitope
    Kim, Eric H.
    Smith, Zachary L.
    Brenneman, Randall J.
    Gay, Hiram A.
    Andriole, Gerald L.
    Michalski, Jeff M.
    Baumann, Brian C.
    JOURNAL OF UROLOGY, 2022, 207 (06): : 1227 - 1234
  • [29] Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
    Hayman, Jonathan
    Phillips, Ryan
    Chen, Di
    Perin, Jamie
    Narang, Amol K.
    Trieu, Janson
    Radwan, Noura
    Greco, Stephen
    Deville, Curtiland, Jr.
    McNutt, Todd
    Song, Daniel Y.
    DeWeese, Theodore L.
    Tran, Phuoc T.
    PROSTATE, 2018, 78 (08): : 623 - 630
  • [30] Identification of Pathologically Favorable Disease in Intermediate-Risk Prostate Cancer Patients: Implications for Active Surveillance Candidates Selection
    Gandaglia, Giorgio
    Schiffmann, Jonas
    Schlomm, Thorsten
    Fossati, Nicola
    Moschini, Marco
    Suardi, Nazareno
    Chun, Felix K. H.
    Montorsi, Francesco
    Graefen, Markus
    Briganti, Alberto
    PROSTATE, 2015, 75 (13): : 1484 - 1491
12345